Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Cash Equivalents
Samsung Biologics Co Ltd
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Cash Equivalents
₩1.1T
|
CAGR 3-Years
160%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Cash Equivalents
₩1.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Cash Equivalents
-₩3.7m
|
CAGR 3-Years
73%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Cash Equivalents
₩15.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
124%
|
CAGR 10-Years
34%
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Cash Equivalents
₩14.6B
|
CAGR 3-Years
127%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
See Also
What is Samsung Biologics Co Ltd's Cash Equivalents?
Cash Equivalents
1.1T
KRW
Based on the financial report for Mar 31, 2024, Samsung Biologics Co Ltd's Cash Equivalents amounts to 1.1T KRW.
What is Samsung Biologics Co Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
85%
Over the last year, the Cash Equivalents growth was -30%. The average annual Cash Equivalents growth rates for Samsung Biologics Co Ltd have been 160% over the past three years , 85% over the past five years .